EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus

Diego M Conti1,2, Backer Vibeke3, Beyer Kirsten4

  • 1The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.

Insights

The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) focused on pediatric action plans for type 2 inflammatory conditions. Early diagnosis and optimized care are crucial for preventing and managing these conditions in children.

Area of Science:

  • Allergy and Airways Diseases
  • Pediatric Inflammation
  • Type 2 Inflammatory Conditions

Background:

  • The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) convened EUFOREUM 2023.
  • Type 2 inflammatory conditions often manifest in childhood, impacting respiratory and skin health.
  • There is a need to enhance early intervention strategies for these conditions.

Purpose of the Study:

  • To highlight pediatric action plans for the prevention and optimized care of type 2 inflammatory conditions.
  • To focus on early-stage diagnosis, avoiding under- or overdiagnosis.
  • To identify areas for improvement in pediatric respiratory and skin disease management.

Main Methods:

  • A multidisciplinary forum (EUFOREUM 2023) involving experts from pediatrics, allergology, pulmonology, dermatology, ENT, and primary care.
  • Keynote lectures and faculty discussions centered on type 2 inflammation in children.
  • A review of key statements and EUFOREA's strategic ambitions.

Main Results:

  • Emphasis on the critical window of childhood for initiating prevention, remission, and disease modification.
  • The forum underscored the importance of a unified, multidisciplinary approach to care.
  • Key statements from EUFOREUM 2023 provide a roadmap for stakeholders.

Conclusions:

  • Raising ambitions for care, including prevention and disease modification, is essential.
  • EUFOREA aims to unite stakeholders to improve care for type 2 inflammatory diseases.
  • The report serves to update stakeholders and foster collaborative action in Europe and beyond.